VIDEO: Practice-changing FDA approvals for AMD

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.

So, there haven't been any recent FDA approvals, but we are on the precipice of hopefully many forthcoming novel therapeutic options in the next few years. So, we're really close to having some novel FDA approvals coming through. And these include things like the Port Delivery System, which is a little implant that's filled with drug that's gradually alluded into the eyes. So, it would obviate the need for monthly injections. And then there are also some therapeutics in the pipeline that are especially formulated polymers, that allow for the medication to be, to kind of stick around the eye for longer time, and deliver a larger dose of medication with just one injection. Also, there are several different companies looking at gene therapy, whereby a gene encodes a therapeutic protein. And so we essentially create an anti-VEGF factory in the eye. And lastly, there are new molecules that are being targeted. For example, one of these is something called Angiopoietin-2 and so these can potentially be combined with the anti-VEGF therapies or sometimes standalone.